InsiderTrades.com logo

OXB Insider Trading

Insider Ownership Percentage: 25.83%
Insider Buying (Last 12 Months): £138,880.25
Insider Selling (Last 12 Months): GBX 0

Oxford Biomedica Insider Trading History Chart

This chart shows the insider buying and selling history at Oxford Biomedica by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oxford Biomedica Share Price & Price History

Current Price: GBX 521
Price Change: ▲ Price Increase of +8 (1.56%)
As of 10/9/2026 11:56 AM ET

This chart shows the closing price history over time for OXB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Oxford Biomedica Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/23/2026Roch DoliveuxInsiderBuy20,250GBX 505£102,262.50
10/20/2025Heather PrestonInsiderBuy6,175GBX 593£36,617.75
8/18/2025Dame Kay DaviesInsiderSell4,563GBX 500£22,815
8/15/2025Roch DoliveuxInsiderBuy67,000GBX 450£301,500
6/17/2025Heather PrestonInsiderBuy11,389GBX 324£36,900.36
11/13/2023Michael HaydenInsiderBuy10,000GBX 193£19,300
See Full Table

SEC Filings (Institutional Ownership Changes) for Oxford Biomedica (LON:OXB)

32.41% of Oxford Biomedica stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Oxford Biomedica logo
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
Read More on Oxford Biomedica

Today's Range

Now: GBX 521
Low: 513
High: 531

50 Day Range

MA: GBX 495.77
Low: 424
High: 591

52 Week Range

Now: GBX 521
Low: 420
High: 952

Volume

147,276 shs

Average Volume

1,071,380 shs

Market Capitalization

£630.66 million

P/E Ratio

N/A

Dividend Yield

4.57%

Beta

1.092

Who are the company insiders with the largest holdings of Oxford Biomedica?

Oxford Biomedica's top insider investors include:
  1. Andrew Heath (Insider)
  2. Catherine Moukheibir (Insider)
  3. Dame Kay Davies (Insider)
  4. Daniel Soland (Insider)
  5. Diggle ,Martin (Insider)
  6. Heather Preston (Insider)
  7. John Dawson (Insider)
  8. Lorenzo Tallarigo (Insider)
  9. Martin Diggle (Insider)
  10. Michael Hayden (Insider)
Learn More about top insider investors at Oxford Biomedica.